文献速递冠心病外科

术前β受体阻滞剂作为冠脉手术质量指标:缺乏疗效证据

Preoperative β-Blockers as a Coronary Surgery Quality Metric: The Lack of Evidence of Efficacy.
PubMed 文献 · Ann Thorac Surg · 2019-09-09

该研究系统检索了11项随机对照试验,评估术前β受体阻滞剂对孤立性冠状动脉旁路移植术后房颤或死亡率的影响。由于所有试验均术后继续用药且方法学异质,无法进行荟萃分析。现有证据不支持将术前24小时内给药作为质量指标。

要点

  • 11项RCT均术后继续使用β受体阻滞剂,无法区分术前与术后给药的获益。
  • β受体阻滞剂/地高辛与安慰剂比较的8项对比中6项显示房颤/室上性心律失常显著减少。
  • 现有RCT证据不支持术前24小时内给药预防术后房颤或短期死亡的质量指标结构。

核心结论

  • 现有RCT证据不支持要求术前24小时内给予β受体阻滞剂以预防CABG术后房颤或短期死亡的质量指标结构。
  • 质量指标应修订以与证据一致,并需进一步研究确定最佳预防时机和方法。

研究设计与样本

  • 系统检索评估术前β受体阻滞剂对孤立性CABG术后房颤或死亡率影响的随机对照试验(RCT)。
  • 共纳入11项RCT。

主要发现

  • 所有RCT均术后继续使用β受体阻滞剂,无法区分术前与术后给药的获益。
  • 因β受体阻滞剂种类、时机、剂量及补充/对照治疗的方法学差异,无法进行荟萃分析。
  • 8项β受体阻滞剂/β受体阻滞剂加地高辛与安慰剂的比较(n=826例)中,6项显示房颤/室上性心律失常显著减少。
  • 3项β受体阻滞剂与胺碘酮的比较(n=444例)中,2项房颤无显著差异,第3项胺碘酮发生率显著更低。
  • 1项RCT比较β受体阻滞剂加胺碘酮与各药单用,联合治疗减少房颤显著优于单用β受体阻滞剂,但不优于单用胺碘酮。

关键数值与推荐

  • 质量指标要求孤立性CABG术前24小时内给予β受体阻滞剂以预防房颤和死亡。
  • β受体阻滞剂/β受体阻滞剂加地高辛与安慰剂比较:8项对比中6项房颤/室上性心律失常显著减少(n=826例)。
  • β受体阻滞剂与胺碘酮比较:3项对比(n=444例)中2项房颤无显著差异,1项胺碘酮显著更低。
  • β受体阻滞剂加胺碘酮 vs 单用β受体阻滞剂:联合治疗房颤显著更少;vs 单用胺碘酮:无显著差异。

临床怎么用

  • 不应仅依据术前24小时内给药这一结构来评价CABG质量。
  • 需重新审视现行质量指标,关注最佳预防时机和方法。

局限性

  • 所有RCT均术后继续使用β受体阻滞剂,无法分离术前给药的独立效应。
  • β受体阻滞剂种类、时机、剂量及补充/对照治疗存在方法学差异,无法进行荟萃分析。
  • 短期死亡率结局罕见且样本量小,无法提供有意义的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two quality measures used in public reporting and value-based payment programs require β-blockers be administered less than 24 hours before isolated coronary artery bypass graft surgery to prevent atrial fibrillation and mortality. Questions have arisen about continued use of these measures. METHODS: We conducted a systematic search for randomized controlled trials (RCTs) examining the impact of preoperative β-blockers on atrial fibrillation or mortality after isolated coronary artery bypass graft surgery to determine what evidence of efficacy supports the measures. RESULTS: We identified 11 RCTs. All continued β-blockers postoperatively, making it unfeasible to separate the benefits of preoperative vs postoperative administration. Meta-analysis was precluded by methodologic variation in β-blocker utilized, timing and dosage, and supplemental and comparison treatments. Of the eight comparisons of β-blockers/β-blocker plus digoxin versus placebo (n = 826 patients), six showed significant reductions in atrial fibrillation/supraventricular arrhythmias. Of the three comparisons (n = 444) of β-blockers versus amiodarone, two found no significant difference in atrial fibrillation; the third showed significantly lower incidence with amiodarone. One RCT compared β-blocker plus amiodarone versus each of those drugs separately; the combination reduced atrial fibrillation significantly better than the β-blocker alone, but not amiodarone alone. Seven RCTs reported short-term mortality, but this outcome was too rare and the sample sizes too small to provide any meaningful comparisons. CONCLUSIONS: Existing RCT evidence does not support the structure of quality measures that require β-blocker administration specifically within 24 hours before coronary artery bypass graft surgery to prevent postoperative atrial fibrillation or short-term mortality. Quality measures should be revised to align with the evidence, and further studies conducted to determine optimal timing and method of prophylaxis.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Filardo G, da Graca B, Sass DM, et al. Preoperative β-Blockers as a Coronary Surgery Quality Metric: The Lack of Evidence of Efficacy. Ann Thorac Surg. 2019. PMID: 31513778. doi:10.1016/j.athoracsur.2019.07.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。